Tesamorelin
GH axisApproved for other indicationsEgrifta
A GHRH analog with an FDA indication for HIV-associated lipodystrophy (branded Egrifta). Brand kits do not use generic BAC math.
- Typical form
- Lyophilized vial
- Typical route
- Subcutaneous
- Display unit
- mg
- Typical vial
- 2 mg
- Half-life (approx.)
- 0.5 h
- Default in-use window
- 14 days
Labeled / commonly logged
Typical protocol
A snapshot of how this compound is logged — not a prescription. You set every number.
- Common range
- 2 mg
- Starting log
- 2 mg
- Cadence
- Daily
- Timing
- Daily SubQ; branded kits use their own diluent
- Duration
- Labeled courses are clinician-directed
Egrifta’s labeled dose for HIV-associated lipodystrophy is 2 mg daily. Brand kits are not generic BAC math. Research vials are a different object.
Reconstitution note
Brand SV/WR kits have their own diluent volumes. Do not assume 2 mL BAC.
Storage
Follow the kit. Research vials: fridge after mix, shorter BUD.
Cautions
Approved indication is not general fat loss. Research vials are not the branded product.
Evidence posture
Labeled product exists; research vials are a different object.